CD6: Thymic Selection and Autoimmunity
CD6:胸腺选择和自身免疫
基本信息
- 批准号:6399112
- 负责人:
- 金额:$ 33.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-01 至 2002-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
CD6 is a T-cell costimulatory molecule expressed on developing thymocytes and on mature T-cells. We hypothesize that a major role of CD6 is to costimulate thymocytes and mature T-cells during low functional avidity interactions with MHC/antigen complexes and to augment resistance of these cells to apoptosis. Mechanisms by which CD6 may contribute to autoimmunity include increased selection of self-reactive thymocytes, increased resistance of thymocytes and/or mature T-cells to apoptosis, and decreases in the stimulation threshold of mature T-cells to self-antigens. We will use complimentary "gain of function" and "loss of function" approaches, including mice bred either to lack or to overexpress CD6, in combination with antigen-specific TCR transgenic mice, thymic organ cultures, and specific soluble reagents which inhibit CD6/CD6 ligand interactions. Potential excesses in CD6-dependent costimulation could also occur if CD6 ligands are over-expressed during T-cell development and/or in tissues affected by autoimmunity. We have identified a new CD6 ligand that is expressed in the thymus, in skin and in synovium. We plan to clone this new CD6 ligand and to study its expression on thymic epithelium during T-cell development. Our specific aims are 1) to test the hypothesis that CD6-dependent costimulation to thymocytes increases functional avidity for AMC/antigen complexes and/or resistance to apoptosis; 2) to test the hypothesis that CD6-dependent costimulation to mature T-cells increases functional avidity and/or resistance to apoptosis; and 3) to clone the novel CD6 ligand and characterize its expression in the thymus. Our long-term goal is to understand the role of CD6 in immunity. One of the major problems in the treatment of autoimmunity is that current therapies reduce both autoimmunity and protective immunity simultaneously. We ultimately want to determine if inhibiting CD6/CD6L interactions can selectively inhibit reactivity with weaker self-antigens without compromising responses to stronger exogenous antigens that are important in innate immunity.
CD6是一种t细胞共刺激分子,在发育中的胸腺细胞和成熟的t细胞上表达。我们假设CD6的主要作用是在与MHC/抗原复合物的低功能相互作用中共同刺激胸腺细胞和成熟t细胞,并增强这些细胞对凋亡的抵抗力。CD6可能促进自身免疫的机制包括增加对自身反应性胸腺细胞的选择,胸腺细胞和/或成熟t细胞对凋亡的抵抗力增加,成熟t细胞对自身抗原的刺激阈值降低。我们将使用互补的“功能获得”和“功能丧失”方法,包括培养缺乏或过表达CD6的小鼠,结合抗原特异性TCR转基因小鼠,胸腺器官培养和抑制CD6/CD6配体相互作用的特异性可溶性试剂。如果CD6配体在t细胞发育和/或受自身免疫影响的组织中过度表达,也可能发生CD6依赖性共刺激的潜在过度。我们已经确定了一种新的CD6配体,它在胸腺、皮肤和滑膜中表达。我们计划克隆这种新的CD6配体,并研究其在t细胞发育过程中在胸腺上皮上的表达。我们的具体目标是:1)验证对胸腺细胞的cd6依赖性共刺激增加AMC/抗原复合物的功能亲和力和/或细胞凋亡抗性的假设;2)验证对成熟t细胞的cd6依赖性共刺激增加功能亲和性和/或抗凋亡的假设;3)克隆新的CD6配体并表征其在胸腺中的表达。我们的长期目标是了解CD6在免疫中的作用。治疗自身免疫的主要问题之一是目前的治疗方法同时降低了自身免疫和保护性免疫。我们最终想要确定抑制CD6/CD6L相互作用是否可以选择性地抑制对较弱自身抗原的反应性,而不影响对先天免疫中重要的较强外源抗原的反应。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency.
PF-3758309(p21 激活激酶的泛亚型抑制剂)阻止 HIV-1 潜伏期重新激活的机制。
- DOI:10.3390/biom13010100
- 发表时间:2023-01-04
- 期刊:
- 影响因子:5.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NORA SINGER其他文献
NORA SINGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NORA SINGER', 18)}}的其他基金
CD6 T LYMPHOCYTE COSTIMULATORY MOLECULE--IMMUNE DEVELOPMENT & AUTOIMMUNE DISEASE
CD6 T 淋巴细胞共刺激分子--免疫发育
- 批准号:
6324599 - 财政年份:2000
- 资助金额:
$ 33.98万 - 项目类别:
CD6 T LYMPHOCYTE COSTIMULATORY MOLECULE--IMMUNE DEVELOPMENT & AUTOIMMUNE DISEASE
CD6 T 淋巴细胞共刺激分子--免疫发育
- 批准号:
6201487 - 财政年份:1999
- 资助金额:
$ 33.98万 - 项目类别:
CD6 T LYMPHOCYTE COSTIMULATORY MOLECULE--IMMUNE DEVELOPMENT & AUTOIMMUNE DISEASE
CD6 T 淋巴细胞共刺激分子--免疫发育
- 批准号:
6100354 - 财政年份:1998
- 资助金额:
$ 33.98万 - 项目类别:
EXPRESSION AND IDENTIFICATION OF CD6 LIGANDS IN PSORIASIS
银屑病中 CD6 配体的表达和鉴定
- 批准号:
6100499 - 财政年份:1998
- 资助金额:
$ 33.98万 - 项目类别:
CD6--TRANSCRIPTIONAL REGULATION & CELLULAR INTERACTIONS
CD6--转录调控
- 批准号:
2077553 - 财政年份:1995
- 资助金额:
$ 33.98万 - 项目类别:
相似海外基金
The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
- 批准号:
DP240102905 - 财政年份:2024
- 资助金额:
$ 33.98万 - 项目类别:
Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23K28188 - 财政年份:2024
- 资助金额:
$ 33.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
- 批准号:
2339172 - 财政年份:2024
- 资助金额:
$ 33.98万 - 项目类别:
Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
- 批准号:
10577518 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
- 批准号:
23H03498 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
- 批准号:
10676407 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
- 批准号:
22KK0277 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
- 批准号:
10599584 - 财政年份:2023
- 资助金额:
$ 33.98万 - 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
- 批准号:
10530023 - 财政年份:2022
- 资助金额:
$ 33.98万 - 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
- 批准号:
10684172 - 财政年份:2022
- 资助金额:
$ 33.98万 - 项目类别: